Looking to a future of multiplex cell engineering

Cell & Gene Therapy Insights 2023; 9(11), 1523–1528

DOI: 10.18609/cgti.2023.199

Published: 11 January
Marco Alessandrini

‘Multiplexing’ has been one of the most prominent buzzwords of 2023 in the advanced therapies space. David McCall, Senior Editor, Cell & Gene Therapy Insights, speaks to Marco Alessandrini, CEO, Antion Biosciences about recent progress with and future targets for tunable multiplex cell engineering platforms.